The complaint alleges that ADMA Biologics violated the Securities Exchange Act of 1934 by disseminating false and misleading information to the market. Specifically, the litigation claims the company failed to disclose a significant related-party transaction and engaged in channel stuffing—the practice of inflating sales figures by shipping excess inventory to distributors to simulate organic demand.

Shareholders who purchased ADMA stock during the specified window have until August 10, 2026, to file for lead plaintiff status. Participation in the lawsuit does not mandate a formal lead role, though the DJS Law Group is actively vetting claimants to build its case. The firm, led by David J. Schwartz, specializes in securities litigation and is currently inviting affected investors to submit their documentation regarding the alleged market manipulation.